Xenico

Monolipid K Forte

Name: Monolipid K Forte
Brand: Xenico
Price: 18.99 GBP
Availability: InStock

£18.99 GBP

W promocji Wyprzedane

Z wliczonymi podatkami. Koszt wysyłki obliczony przy realizacji zakupu.

Ilość

Product Details

Monolipid K^® forte is a premium natural preparation containing in one capsule a unique combination of Bergamot Fruit Extract (Citrus bergamia Risso) standardised to 40% BPF (Bergamot-derived Polyphenolic Fraction) polyphenols in the highest dose of 400 mg and active rice red yeast extract standardised for Monacolin K, which helps to maintain normal cholesterol. This, along with its effectiveness, was confirmed by the European Food Safety Authority (EFSA). It also certified the role of Monacolin K in the prevention of cardiovascular disease.

The composition of Monolipid K^® forte was developed on the basis of the latest medical knowledge by scientists from independent research units.

The product is 100% natural. Monolipid K^® forte does not contain sugar, salt, gluten, casein and lactose. Produced without the use of artificial preservatives, fragrances and unnecessary colouring agents. The preparation is safe for diabetics. The Monolipid K^® forte product uses the innovative V-Caps^® plant-based capsule.

Vcaps^® are specialized, patented plant-based capsules made of HPMC (plant cellulose) and water – without preservatives and gelatin. Recommended for vegans and vegetarians.

Studies regarding the dosage of 3 mg:
Regarding the amount of 3 mg of monacolin K in a dietary supplement, available studies still show good effects of monacolin K despite the reduced dose. Participants in the supplementation group consumed 3 mg of monacolin K and 200 μg of folic acid daily. In the supplementation group, after 12 weeks, a significant (P < .001) reduction in LDL-C (-14.8%), total cholesterol (-11.2%) and homocysteine (-12.5%) was determined. A total of 51% of RYR-treated participants achieved a cut-off LDL-C level of <4.14 mmol/L, and 26% achieved a cut-off homocysteine level of <10 μmol/L. There were no significant changes in the placebo group. Other parameters remained unchanged and no intolerance or serious adverse events were observed. In conclusion, a low daily dose of 3 mg of monacolin K has been shown to reduce LDL-C as a risk factor for cardiovascular disease.